<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04280497</url>
  </required_header>
  <id_info>
    <org_study_id>APHP191110</org_study_id>
    <secondary_id>2020-000296-21</secondary_id>
    <nct_id>NCT04280497</nct_id>
  </id_info>
  <brief_title>Rapid Recognition of Corticosteroid Resistant or Sensitive Sepsis</brief_title>
  <acronym>RECORDS</acronym>
  <official_title>A Multicentre Concealed‐Allocation Multi-arms Blinded Randomized Controlled Trial to Identify the Best Sepsis Population for Corticotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Versailles Saint-Quentin-en-Yvelines University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université Paris Saclay</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université Paris Est Créteil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Commissariat A L'energie Atomique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beckman Coulter, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lumedix</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Elice</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biothelis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main objective and primary endpoint: To compare the effect hydrocortisone plus
      fludrocortisone vs. placebo on a composite of death or persistent organ dysfunction - defined
      as continued dependency on mechanical ventilation, new renal replacement therapy, or
      vasopressors - assessed at 90 days on intensive care unit (ICU) adults and having different
      biological profiles for immune responses and corticosteroids bioactivity.

      Secondary objectives and endpoints:

        -  Mortality and health-related quality of life at 6 months;

        -  Daily organ function (SOFA score days 1, 2, 3, 4, 7, 10, 14, 28, and 90);

        -  Daily secondary infections (up to 90 days)

        -  Daily blood and urinary levels of glucose, sodium and potassium (up to 28 day)

        -  Daily gastroduodenal bleeding (up to 28 day)

        -  Daily cognitive function and muscles' strength (days 1 to 28, 90 and 180 days).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The potential benefits of a lower dose ( ≤ 400 mg of hydrocortisone or equivalent per day),
      and a longer duration at full dose ( ≥ three days) of treatment, have been investigated in
      numerous randomized controlled trials over the past three decades. In the past two years,
      guidelines for clinical practices about corticosteroids use in sepsis have been released. All
      but one of the guidelines, recommended against the use of corticosteroids in sepsis, except
      in patients with septic shock and poorly responsive to fluid replacement and vasopressor
      therapy. Some guidelines suggested that corticosteroids should be given as a continuous
      infusion rather than intermittent boluses.

      Corticosteroids survival benefit is not affected by age, gender, disease severity, type of
      infection, source of infection, or type of pathogens. There is currently no diagnostic test
      for CS sensitivity/resistance in sepsis. The scientific community is competing to identify
      markers delineating between patients who draw survival benefit from corticosteroids
      (CS-sensitive sepsis) and those who may be harmed (CS-resistant sepsis). In sepsis, the
      deregulated response may result in systemic inflammation and organs damage, or immune paresis
      and secondary infections. Obviously, patients with systemic inflammation may benefit from CS
      whereas those with immune paresis may deteriorate. The study team had have looked for an
      interaction between survival in response to corticosteroids and the presence of CIRCI
      according to the ACTH test results (cortisol increment of less than 9µg/dL). The benefits
      from corticosteroids were more important in patients with CIRCI in the Ger-Inf-05 trial but
      not in the APROCCHS trial. Thus, current sepsis guidelines suggest that the ACTH test may not
      reliably guide the use of corticosteroids. Indeed, this test provides information neither on
      corticosteroids bioactivity nor on patient's immune status, when this information should
      precede any corticotherapy. Recent studies suggested that a transcriptomic signature based on
      100 genes may identify a subset of paediatric sepsis that had increased risk of death when
      exposed to corticosteroids. Another study found transcriptomic based sepsis response
      signatures (SRS) associated with immune paresis (SRS1) or with systemic inflammation (SRS 2).
      In this study, patients with a SRS 2 transcriptomic signature had significantly higher
      mortality when treated with hydrocortisone. Thus, we have started exploring the mechanisms of
      sensitivity/resistance to corticosteroids in sepsis, namely by investigating endocan, as a
      surrogate of patient's inflammatory status, and GILZ expression as a marker of
      corticosteroids bioactivity.

      This is a new multicentre concealed-allocation multi-arms, parallel-group, adaptive blinded
      randomized controlled trial. The overall objective of the trial is to determine whether
      different signatures of immune status and/or corticosteroids biological activity influence
      the responses to hydrocortisone plus fludrocortisone of adults with sepsis. To remain
      pragmatic, this trial has broad eligibility criteria and includes all patients admitted to
      the ICU with a primary diagnosis of sepsis. Patients will be randomly assigned to
      hydrocortisone plus fludrocortisone or placebo for 7 days, targeting 1800 patients with full
      follow-up up to 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2020</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-month mortality</measure>
    <time_frame>Daily up to 3 months</time_frame>
    <description>Patient's vital status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistent organ dysfunction</measure>
    <time_frame>At baseline, 1 month and 3 months</time_frame>
    <description>Persistent organ dysfunction (defined as continued dependency on mechanical ventilation, renal replacement therapy, or vasopressors) and with SOFA score ≤6 up to 90 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-month mortality</measure>
    <time_frame>At 6 months</time_frame>
    <description>Patient's vital status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life at 6 months</measure>
    <time_frame>At 6 months</time_frame>
    <description>Health-related quality of life will be assessed by HRQoL questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ function</measure>
    <time_frame>At baseline, days 1, 2, 3, 4, 7, 10, 14, 28.</time_frame>
    <description>SOFA score will be used to evaluate organ function including renal function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily secondary infections</measure>
    <time_frame>Daily up to 90 days</time_frame>
    <description>All secondary infections (others sources of infections) will be documented daily</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypernatremia: sodium rate</measure>
    <time_frame>Daily up to 28 days</time_frame>
    <description>Blood lever of sodium will be tested daily.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypernatremia: potassium rate</measure>
    <time_frame>Daily up to 28 days</time_frame>
    <description>Blood lever of potassium will be tested daily.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperglycaemia</measure>
    <time_frame>Daily up to 28 days</time_frame>
    <description>Blood levels of glucose will be tested daily.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastroduodenal bleeding</measure>
    <time_frame>Daily up to 28 days</time_frame>
    <description>Gastroduodenal bleeding will be observed daily. Bleeding in the gastrointestinal tract defined by clinical evidence of active bleeding and need for blood transfusion or hemostatic endoscopic or surgical procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological cognitive function</measure>
    <time_frame>Daily up to 28 days, day 90 and day 180.</time_frame>
    <description>Neurological cognitive function will be evaluated, dysfunction defined as by low score on the PROMIS Adult cognitive function score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuromuscular strength</measure>
    <time_frame>Daily up to 28 days, day 90 and day 180.</time_frame>
    <description>Neuromuscular weakness defined as a grade of 2 or more on Muscular Disability Rating Scale (MDRS).</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Biomarker CIRCI neg: Corticosteroid arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biomarker CIRCI neg: Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biomarker endocan: Corticosteroid arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biomarker endocan: Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biomarker GILZ: Corticosteroid arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biomarker GILZ: Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biomarker CPD: Corticosteroid arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biomarker CPD: Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biomarker Transcriptomic SRS: Corticosteroid arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biomarker Transcriptomic SRS: Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biomarker Endotype B: Corticosteroid arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrocortisone plus fludrocortisone as treatment: hydrocortisone hemisuccinate and 9 alpha fludrocortisone as experimental treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biomarker Endotype B: Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: hydrocortisone placebo and 9 alpha fludrocortisone placebo as placebo treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration procedures</intervention_name>
    <description>Hydrocortisone hemisuccinate / hydrocortisone placebo will be given as 50 mg intravenous bolus every 6 hours;
9 alpha fludrocortisone / 9 alpha fludrocortisone placebo will be given as a 50 μg tablet via a nasogastric tube once per day in the morning.
Study drugs will be started immediately after randomization (day 0 of the study), until discharge from ICU for a maximal duration of 7 days. Study drugs will be stopped without tapering off.</description>
    <arm_group_label>Biomarker CIRCI neg: Corticosteroid arm</arm_group_label>
    <arm_group_label>Biomarker CIRCI neg: Placebo arm</arm_group_label>
    <arm_group_label>Biomarker CPD: Corticosteroid arm</arm_group_label>
    <arm_group_label>Biomarker CPD: Placebo arm</arm_group_label>
    <arm_group_label>Biomarker Endotype B: Corticosteroid arm</arm_group_label>
    <arm_group_label>Biomarker Endotype B: Placebo arm</arm_group_label>
    <arm_group_label>Biomarker GILZ: Corticosteroid arm</arm_group_label>
    <arm_group_label>Biomarker GILZ: Placebo arm</arm_group_label>
    <arm_group_label>Biomarker Transcriptomic SRS: Corticosteroid arm</arm_group_label>
    <arm_group_label>Biomarker Transcriptomic SRS: Placebo arm</arm_group_label>
    <arm_group_label>Biomarker endocan: Corticosteroid arm</arm_group_label>
    <arm_group_label>Biomarker endocan: Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient ≥18 years old;

          -  Admitted to ICU;

          -  Patient with proven or suspected infection as the main diagnosis;

          -  Community acquired pneumonia related sepsis or vasopressors dependency
             (norepinephrine, epinephrine, vasopressin, dopamine, phenylephrine) or septic shock
             (vasopressor to maintain mean blood pressure of at least 65 mmHg and lactate levels
             above 2 mmol/l) or acute respiratory distress syndrome (ARDS: a- acute onset, i.e.
             within one week of an apparent clinical insult and with progression of respiratory
             syndrome, b- bilateral opacities on chest imaging not explained by other pulmonary
             pathologies, e.g. pleural effusion, atelectasis, nodules etc, c- no evidence for heart
             failure or volume overload, d- PaO2/FiO2 ≤ 300 mm Hg, - PEEP ≥ 5 cm H2O;

          -  Patients who have been tested for RECORDS specific biomarkers:

               1. CIRCI neg

               2. Endocan &lt; 2 ng/L

               3. GILZ &lt; x (to be defined)

               4. CPD pos

               5. Transcriptomic SRS2

               6. Endotype B;

          -  Patient who has signed the informed consent whenever he/she is able to consent, if
             not, patient's representative signed ascent whenever he/she is present at inclusion;

          -  Patient affiliated to a social security system or to an universal health coverage
             (Couverture Maladie Universelle (CMU) in France;

          -  Patient under guardianship or curatorship will be included;

          -  Patient in case of simple emergency (legal definition) will be included.

        Exclusion Criteria:

          -  Pregnant woman;

          -  Expected death or withdrawal of life-sustaining treatments within 48 hours;

          -  Previously enrolled in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Djillali ANNANE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of medical and surgical Intensive Care Unit, - Raymond Poincaré Hospital - APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Djillali ANNANE, MD, PhD</last_name>
    <phone>+33 1 47 10 77 87</phone>
    <email>djillali.annane@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of medical and surgical Intensive Care Unit, Raymond Poincaré Hospital - APHP</name>
      <address>
        <city>Garches</city>
        <state>Hauts-de-Seine</state>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Annane D, Pastores SM, Rochwerg B, Arlt W, Balk RA, Beishuizen A, Briegel J, Carcillo J, Christ-Crain M, Cooper MS, Marik PE, Umberto Meduri G, Olsen KM, Rodgers S, Russell JA, Van den Berghe G. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Med. 2017 Dec;43(12):1751-1763. doi: 10.1007/s00134-017-4919-5. Epub 2017 Sep 21. Erratum in: Intensive Care Med. 2018 Feb 23;:.</citation>
    <PMID>28940011</PMID>
  </reference>
  <reference>
    <citation>Lamontagne F, Rochwerg B, Lytvyn L, Guyatt GH, Møller MH, Annane D, Kho ME, Adhikari NKJ, Machado F, Vandvik PO, Dodek P, Leboeuf R, Briel M, Hashmi M, Camsooksai J, Shankar-Hari M, Baraki MK, Fugate K, Chua S, Marti C, Cohen D, Botton E, Agoritsas T, Siemieniuk RAC. Corticosteroid therapy for sepsis: a clinical practice guideline. BMJ. 2018 Aug 10;362:k3284. doi: 10.1136/bmj.k3284.</citation>
    <PMID>30097460</PMID>
  </reference>
  <reference>
    <citation>Rochwerg B, Oczkowski SJ, Siemieniuk RAC, Agoritsas T, Belley-Cote E, D'Aragon F, Duan E, English S, Gossack-Keenan K, Alghuroba M, Szczeklik W, Menon K, Alhazzani W, Sevransky J, Vandvik PO, Annane D, Guyatt G. Corticosteroids in Sepsis: An Updated Systematic Review and Meta-Analysis. Crit Care Med. 2018 Sep;46(9):1411-1420. doi: 10.1097/CCM.0000000000003262.</citation>
    <PMID>29979221</PMID>
  </reference>
  <reference>
    <citation>Nishida O, Ogura H, Egi M, Fujishima S, Hayashi Y, Iba T, Imaizumi H, Inoue S, Kakihana Y, Kotani J, Kushimoto S, Masuda Y, Matsuda N, Matsushima A, Nakada TA, Nakagawa S, Nunomiya S, Sadahiro T, Shime N, Yatabe T, Hara Y, Hayashida K, Kondo Y, Sumi Y, Yasuda H, Aoyama K, Azuhata T, Doi K, Doi M, Fujimura N, Fuke R, Fukuda T, Goto K, Hasegawa R, Hashimoto S, Hatakeyama J, Hayakawa M, Hifumi T, Higashibeppu N, Hirai K, Hirose T, Ide K, Kaizuka Y, Kan'o T, Kawasaki T, Kuroda H, Matsuda A, Matsumoto S, Nagae M, Onodera M, Ohnuma T, Oshima K, Saito N, Sakamoto S, Sakuraya M, Sasano M, Sato N, Sawamura A, Shimizu K, Shirai K, Takei T, Takeuchi M, Takimoto K, Taniguchi T, Tatsumi H, Tsuruta R, Yama N, Yamakawa K, Yamashita C, Yamashita K, Yoshida T, Tanaka H, Oda S. The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016). Acute Med Surg. 2018 Feb 5;5(1):3-89. doi: 10.1002/ams2.322. eCollection 2018 Jan.</citation>
    <PMID>29445505</PMID>
  </reference>
  <reference>
    <citation>Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar;43(3):304-377. doi: 10.1007/s00134-017-4683-6. Epub 2017 Jan 18.</citation>
    <PMID>28101605</PMID>
  </reference>
  <reference>
    <citation>Tavaré A, O'Flynn N. Recognition, diagnosis, and early management of sepsis: NICE guideline. Br J Gen Pract. 2017 Apr;67(657):185-186. doi: 10.3399/bjgp17X690401.</citation>
    <PMID>28360070</PMID>
  </reference>
  <reference>
    <citation>van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 2017 Jul;17(7):407-420. doi: 10.1038/nri.2017.36. Epub 2017 Apr 24. Review.</citation>
    <PMID>28436424</PMID>
  </reference>
  <reference>
    <citation>Wong HR, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, Weiss SL, Fitzgerald J, Checchia PA, Meyer K, Shanley TP, Quasney M, Hall M, Gedeit R, Freishtat RJ, Nowak J, Shekhar RS, Gertz S, Dawson E, Howard K, Harmon K, Beckman E, Frank E, Lindsell CJ. Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med. 2015 Feb 1;191(3):309-15. doi: 10.1164/rccm.201410-1864OC.</citation>
    <PMID>25489881</PMID>
  </reference>
  <reference>
    <citation>Antcliffe DB, Burnham KL, Al-Beidh F, Santhakumaran S, Brett SJ, Hinds CJ, Ashby D, Knight JC, Gordon AC. Transcriptomic Signatures in Sepsis and a Differential Response to Steroids. From the VANISH Randomized Trial. Am J Respir Crit Care Med. 2019 Apr 15;199(8):980-986. doi: 10.1164/rccm.201807-1419OC.</citation>
    <PMID>30365341</PMID>
  </reference>
  <reference>
    <citation>Annane D, Pastores SM, Arlt W, Balk RA, Beishuizen A, Briegel J, Carcillo J, Christ-Crain M, Cooper MS, Marik PE, Meduri GU, Olsen KM, Rochwerg B, Rodgers SC, Russell JA, Van den Berghe G. Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Intensive Care Med. 2017 Dec;43(12):1781-1792. doi: 10.1007/s00134-017-4914-x. Epub 2017 Sep 21. Review.</citation>
    <PMID>28940017</PMID>
  </reference>
  <reference>
    <citation>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.</citation>
    <PMID>26903338</PMID>
  </reference>
  <reference>
    <citation>ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012 Jun 20;307(23):2526-33. doi: 10.1001/jama.2012.5669.</citation>
    <PMID>22797452</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Corticosteroid</keyword>
  <keyword>intensive care unit</keyword>
  <keyword>CS-resistant Sepsis</keyword>
  <keyword>CS-sensitive Sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

